The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

The approval is for Eylea to treat macular edema following retinal vein occlusion with up to every eight-week dosing after an initial dosing period. The FDA also approved a monthly dosing option for ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

Menlo Park resident Carmen Caricchio is on a quest to cure childhood inherited retinal diseases, a group of rare conditions that cause the degeneration of the retina and can lead to vision impairment ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...